Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer
Weekly Trastuzumab (Herceptin) and Irinotecan in Patients With HER-2 Positive Advanced Breast Cancer: A Phase II Trial
Status: Enrolling
Updated:  1/12/2018
UCSF Helen Diller Family Comprehensive Cancer Center
680
mi
from 98109
San Francisco, CA
Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer
Weekly Trastuzumab (Herceptin) and Irinotecan in Patients With HER-2 Positive Advanced Breast Cancer: A Phase II Trial
Status: Enrolling
Updated: 1/12/2018
UCSF Helen Diller Family Comprehensive Cancer Center
680
mi
from 98109
San Francisco, CA
Click here to add this to my saved trials
Lenalidomide Maintenance Therapy After High Dose BEAM With or Without Rituximab
Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  1/13/2018
University of Kansas Hospital - Westwood Cancer Center
1504
mi
from 98109
Westwood, KA
Lenalidomide Maintenance Therapy After High Dose BEAM With or Without Rituximab
Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 1/13/2018
University of Kansas Hospital - Westwood Cancer Center
1504
mi
from 98109
Westwood, KA
Click here to add this to my saved trials
Lenalidomide Maintenance Therapy After High Dose BEAM With or Without Rituximab
Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  1/13/2018
Univ of Nebraska Med Ctr
1366
mi
from 98109
Omaha, NE
Lenalidomide Maintenance Therapy After High Dose BEAM With or Without Rituximab
Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 1/13/2018
Univ of Nebraska Med Ctr
1366
mi
from 98109
Omaha, NE
Click here to add this to my saved trials
Lenalidomide Maintenance Therapy After High Dose BEAM With or Without Rituximab
Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  1/13/2018
Seidman Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center
mi
from 98109
Cleveland, OH
Lenalidomide Maintenance Therapy After High Dose BEAM With or Without Rituximab
Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 1/13/2018
Seidman Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center
mi
from 98109
Cleveland, OH
Click here to add this to my saved trials
Acolbifene in Preventing Cancer in Premenopausal Women at High Risk of Breast Cancer
Phase II Study of Acolbifene in Pre-Menopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  1/15/2018
University of Kansas Medical Center
1495
mi
from 98109
Kansas City, KA
Acolbifene in Preventing Cancer in Premenopausal Women at High Risk of Breast Cancer
Phase II Study of Acolbifene in Pre-Menopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 1/15/2018
University of Kansas Medical Center
1495
mi
from 98109
Kansas City, KA
Click here to add this to my saved trials
Accelerated Hypofractionated Radiotherapy (AHF-RT) for the Treatment of Breast Cancer
A Phase II Study of Accelerated Hypofractionated Radiotherapy (AHF-RT) After Breast Conserving Surgery (BCS) in Medically Underserved Patients
Status: Enrolling
Updated:  1/15/2018
James Graham Brown Cancer Center
1939
mi
from 98109
Louisville, KY
Accelerated Hypofractionated Radiotherapy (AHF-RT) for the Treatment of Breast Cancer
A Phase II Study of Accelerated Hypofractionated Radiotherapy (AHF-RT) After Breast Conserving Surgery (BCS) in Medically Underserved Patients
Status: Enrolling
Updated: 1/15/2018
James Graham Brown Cancer Center
1939
mi
from 98109
Louisville, KY
Click here to add this to my saved trials
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Enrolling
Updated:  1/15/2018
University of Arkansas for Medical Sciences
1780
mi
from 98109
Little Rock, AR
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Enrolling
Updated: 1/15/2018
University of Arkansas for Medical Sciences
1780
mi
from 98109
Little Rock, AR
Click here to add this to my saved trials
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Northwestern University Medical Center
1732
mi
from 98109
Chicago, IL
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Northwestern University Medical Center
1732
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Enrolling
Updated:  1/15/2018
University of Kansas Medical Center
1495
mi
from 98109
Kansas City, KA
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Enrolling
Updated: 1/15/2018
University of Kansas Medical Center
1495
mi
from 98109
Kansas City, KA
Click here to add this to my saved trials
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Dana-Farber Cancer Institute
2485
mi
from 98109
Boston, MA
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Dana-Farber Cancer Institute
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Ohio State Unviersity Medical Center
2007
mi
from 98109
Columbus, OH
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Ohio State Unviersity Medical Center
2007
mi
from 98109
Columbus, OH
Click here to add this to my saved trials
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Enrolling
Updated:  1/15/2018
University of Oklahoma Health Sciences Center
1524
mi
from 98109
Oklahoma City, OK
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Enrolling
Updated: 1/15/2018
University of Oklahoma Health Sciences Center
1524
mi
from 98109
Oklahoma City, OK
Click here to add this to my saved trials
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Univ of Washington
2
mi
from 98109
Seattle, WA
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Univ of Washington
2
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
A Dose-escalation Study in Subjects With Advanced Malignancies
A Phase I, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of INCB024360 in Patients With Advanced Malignancies
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
2373
mi
from 98109
Philadelphia, PA
A Dose-escalation Study in Subjects With Advanced Malignancies
A Phase I, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of INCB024360 in Patients With Advanced Malignancies
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
2373
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
A Dose-escalation Study in Subjects With Advanced Malignancies
A Phase I, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of INCB024360 in Patients With Advanced Malignancies
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
1733
mi
from 98109
Chicago, IL
A Dose-escalation Study in Subjects With Advanced Malignancies
A Phase I, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of INCB024360 in Patients With Advanced Malignancies
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
1733
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
2079
mi
from 98109
Birmingham, AL
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
2079
mi
from 98109
Birmingham, AL
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
1867
mi
from 98109
Indianapolis, IN
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
1867
mi
from 98109
Indianapolis, IN
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
1939
mi
from 98109
Louisville, KY
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
1939
mi
from 98109
Louisville, KY
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
1903
mi
from 98109
Ann Arbor, MI
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
1903
mi
from 98109
Ann Arbor, MI
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
1184
mi
from 98109
Albuquerque, NM
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
1184
mi
from 98109
Albuquerque, NM
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
1565
mi
from 98109
Tulsa, OK
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
1565
mi
from 98109
Tulsa, OK
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
147
mi
from 98109
Portland, OR
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
147
mi
from 98109
Portland, OR
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
1760
mi
from 98109
Hot Springs, AR
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
1760
mi
from 98109
Hot Springs, AR
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
953
mi
from 98109
Burbank, CA
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
953
mi
from 98109
Burbank, CA
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
962
mi
from 98109
Los Angeles, CA
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
962
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
961
mi
from 98109
Santa Monica, CA
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
961
mi
from 98109
Santa Monica, CA
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
1020
mi
from 98109
Denver, CO
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
1020
mi
from 98109
Denver, CO
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
2412
mi
from 98109
Stamford, CT
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
2412
mi
from 98109
Stamford, CT
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
2701
mi
from 98109
Boynton Beach, FL
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
2701
mi
from 98109
Boynton Beach, FL
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
1713
mi
from 98109
Elks Grove Village, IL
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
1713
mi
from 98109
Elks Grove Village, IL
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
1306
mi
from 98109
Sioux City, IA
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
1306
mi
from 98109
Sioux City, IA
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
2005
mi
from 98109
Lexington, KY
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
2005
mi
from 98109
Lexington, KY
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
2454
mi
from 98109
Worcester, MA
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
2454
mi
from 98109
Worcester, MA
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
1933
mi
from 98109
Detroit, MI
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
1933
mi
from 98109
Detroit, MI
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
1794
mi
from 98109
Grand Rapids, MI
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
1794
mi
from 98109
Grand Rapids, MI
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
1908
mi
from 98109
Novi, MI
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
1908
mi
from 98109
Novi, MI
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
1393
mi
from 98109
Minneapolis, MN
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
1393
mi
from 98109
Minneapolis, MN
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
2385
mi
from 98109
Voorhees, NJ
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
2385
mi
from 98109
Voorhees, NJ
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
2414
mi
from 98109
Lake Success, NY
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
2414
mi
from 98109
Lake Success, NY
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
2341
mi
from 98109
Durham, NC
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
2341
mi
from 98109
Durham, NC
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
2238
mi
from 98109
Hickory, NC
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
2238
mi
from 98109
Hickory, NC
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
2052
mi
from 98109
Canton, OH
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
2052
mi
from 98109
Canton, OH
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
1961
mi
from 98109
Dayton, OH
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
1961
mi
from 98109
Dayton, OH
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
251
mi
from 98109
Bend, OR
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
251
mi
from 98109
Bend, OR
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
2132
mi
from 98109
Pittsburgh, PA
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
2132
mi
from 98109
Pittsburgh, PA
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
2113
mi
from 98109
Knoxville, TN
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
2113
mi
from 98109
Knoxville, TN
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
1790
mi
from 98109
San Antonio, TX
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
1790
mi
from 98109
San Antonio, TX
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
2348
mi
from 98109
Richmond, VA
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
2348
mi
from 98109
Richmond, VA
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
1646
mi
from 98109
Green Bay, WI
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
1646
mi
from 98109
Green Bay, WI
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
2616
mi
from 98109
Fort Myers, FL
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
2616
mi
from 98109
Fort Myers, FL
Click here to add this to my saved trials